UNSPSC 51361913: Difebarbamate

This classification denotes a sedative and hypnotic with the molecular formula C28H42N4O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7EE4K616KK, chemically known as 1,3-bis(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid dicarbamate ester but generally known as difebarbamate, which bears US NIH Compound Identifier 71880. European Medicines Agency schedules Difebarbamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07116MIG.

UNSPSC 51361913 Difebarbamate is a Commodity code covering pharmaceutical products, though the recent state and local opportunities tagged under it span a broader range of pharmacy and drug-management procurement than the code name alone suggests. State and local buyers under this code are purchasing naloxone and drug deactivation systems for community health programs, generic pharmaceuticals and over-the-counter products through cooperative purchasing alliances, and exploring direct-to-manufacturer prescription fulfillment models. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing organizations administering contracts on behalf of participating state and local government facilities. The scope reflects a mix of emergency-response pharmaceuticals, routine generic medication supply, and emerging pharmacy benefit management restructuring at the state level.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct state-level relationships with pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) to participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026.